Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMaT platform trial for Mycobacterium abscessus pulmonary disease
ACTRN12618001831279Phase 2Recruiting
- Sponsor
- The University of Queensland
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of amikacin, tigecycline, imipenem, cefoxitin, azithromycin and 8 more in Mycobacterium abscessus lung disease (6 arms), sponsored by The University of Queensland. Primary endpoints: Primary intervention program endpoint, Nested Study A1.1 and 2 more. Started Mar 2020; status: recruiting.
02
Drugs
amikacintigecyclineimipenemcefoxitinazithromycin
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on ACTRN12618001831279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001831279.